Xu Cong Claire
Xu Cong Claire, EVP, CD, reported a transaction classified as exercise at NovaBridge Biosciences involving 4079.000000 shares for an estimated $0.00. Reported holdings after the transaction were 28558.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Aug 30, 2026
- Filing date
- Sep 01, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
NBP price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0002114309-26-000007 Restricted Share Units
- Transaction date
- Aug 30, 2026 Filed Sep 01, 2026, 10:00 PM · 2d delay
- Shares
- 4,079 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 28,558 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
EVP, Clinical Development
- F1
The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
- F2
Reported securities are represented by 4,079 ADSs.
- F3
Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
- F4
Reported securities are represented by 133,688 ADSs.
- F5
Reported securities are represented by 1,427 ADSs.
- F6
Reported sales price represents the converted sales price of the ADSs of $1.8186.
- F7
Reported securities are represented by 132,261 ADSs.
- F8
Reported securities represent ADSs.
- F9
On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting…
0 other transactions
0 recent txs